Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Nov;26(5):509–513. doi: 10.1111/j.1365-2125.1988.tb05290.x

Reversal of histamine-induced bronchoconstriction by the H1-receptor antagonist levocabastine: a potential model for efficacy in anaphylaxis.

R E Ferner 1, C Ward 1, C Kelly 1, M Connolly 1, D N Bateman 1, M D Rawlins 1
PMCID: PMC1386627  PMID: 2905152

Abstract

1. The rate of onset and magnitude of the effect of levocabastine, a potent H1-receptor antagonist, in reversing histamine-induced bronchoconstriction were determined in a double-blind cross-over trial against saline placebo. Histamine was administered by nebuliser so that forced expiratory volume in 1 second (FEV1) was reduced to 80-75% of baseline FEV1 in 10 men with mildly or moderately responsive airways and the effects of intravenous injection of saline or saline + 200 micrograms levocabastine were studied. 2. The maximum rate of recovery of FEV1 was 7[2-10]% min-1 (median [range]) in the first 5 min after levocabastine injection, but only 4[1-7]% min-1 after saline alone (P less than 0.05). 3. The median area under the recovery curve of FEV1 from 0 to 30 min after injection was 405 [228-498]% basal FEV1 X min after levocabastine and 301[98-502]% basal FEV1 X min after saline alone (P less than 0.002). 4. FEV1 returned to 90% of baseline within 30 min in all subjects after levocabastine, but not after saline alone (P less than 0.002). 5. Histamine-induced bronchoconstriction was relieved more quickly by levocabastine than saline alone. This model may have application to the study of drugs used in the treatment of anaphylaxis.

Full text

PDF
509

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bach M. K. Mediators of anaphylaxis and inflammation. Annu Rev Microbiol. 1982;36:371–413. doi: 10.1146/annurev.mi.36.100182.002103. [DOI] [PubMed] [Google Scholar]
  2. Bateman D. N., Chapman P. H., Rawlins M. D. The effects of astemizole on histamine-induced weal and flare. Eur J Clin Pharmacol. 1983;25(4):547–551. doi: 10.1007/BF00542126. [DOI] [PubMed] [Google Scholar]
  3. Dale H. H., Laidlaw P. P. The physiological action of beta-iminazolylethylamine. J Physiol. 1910 Dec 31;41(5):318–344. doi: 10.1113/jphysiol.1910.sp001406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hendrick D. J., Fabbri L. M., Hughes J. M., Banks D. E., Barkman H. W., Jr, Connolly M. J., Jones R. N., Weill H. Modification of the methacholine inhalation test and its epidemiologic use in polyurethane workers. Am Rev Respir Dis. 1986 Apr;133(4):600–604. doi: 10.1164/arrd.1986.133.4.600. [DOI] [PubMed] [Google Scholar]
  5. SCHILD H. O., HAWKINS D. F., MONGAR J. L., HERXHEIMER H. Reactions of isolated human asthmatic lung and bronchial tissue to a specific antigen; histamine release and muscular contraction. Lancet. 1951 Sep 1;2(6679):376–382. doi: 10.1016/s0140-6736(51)91554-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES